TT-034 / Benitec BioPharma - LARVOL DELTA

LncRNA PEAMIR inhibits apoptosis and inflammatory response in PM2.5 exposure aggravated myocardial ischemia/reperfusion injury as a competing endogenous RNA of miR-29b-3p. (PubMed, Nanotoxicology) - "Then, based on results of sequencing and RT-qPCR, we selected NONRATT003473.2 in the follow-up experiments and named this lncRNA as PM2.5 exposure aggravated myocardial I/R injury lncRNA (PEAMIR)...Our subsequent experiments validated the regulatory relationship between PEAMIR-miR-29b-3p ceRNA pair and PI3K (p85a)/Akt/GSK3b/p53 cascade pathway. In conclusion, our study demonstrated the role and mechanism of PEAMIR in the augment of I/R injury under PM2.5 exposure, suggesting a promising strategy for the prevention and treatment of I/R injury under PM2.5 exposure."

Journal • Cardiovascular • Immunology • Myocardial Ischemia • Reperfusion Injury

Benitec Biopharma adds fourth site for hepatitis C clinical trial for TT-034 (Hepatitis News Today) - "Clinical stage biotechnology company, Benitec Biopharma Ltd., recently announced it has opened a 4th additional site to carry out ongoing Phase 1/2a studies on TT-034...The new site is located at the Methodist Health System Clinical Research Institute in Dallas, Texas and has initiated pre-screening of patients under the guidance of lead investigator gastroenterologist and hepatologist, Dr. Parvez Mantry."

Trial status • Hepatitis C Virus

Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034. (clinicaltrials.gov) - P1/2; N=9; Active, not recruiting; Sponsor: Tacere Therapeutics, Inc.; Enrolling by invitation ➔ Active, not recruiting; N=14 ➔ 9

Enrollment change • Enrollment closed • Biosimilar • Hepatitis C Virus • Immunology

HCV trial update (Benitec Press Release) - P1/2a, N=14; NCT01899092; Sponsor: Tacere Therapeutics; "Dosing of the second patient continues to take longer than anticipated due to the unexpected failure of two patients being monitored for eligibility at Duke Clinical Research Centre (Duke)....changes to patient recruitment are designed to address the delay experienced in dosing of the second patient, and support the recruitment of subsequent
patient cohorts."

Trial status • Hepatitis C Virus

Benitec announces results from phase I/IIa clinical study of TT-034 (Benitec Press Release) - P1/2, N=9; NCT01899092; Sponsor: Tacere Therapeutics, Inc; "Benitec Biopharma…announces that its phase I/IIa clinical study for TT-034 has met its 24-week primary endpoint...demonstrates that TT-034 was well tolerated and had a favorable safety profile in subjects chronically infected with the hepatitis C virus (HCV). While transduction of hepatic tissues was seen, there was no significant decrease in viral load in treated patients, which was a secondary endpoint of the study…There were only three adverse events (diarrhoea, light-headedness and bradycardia) considered possibly related to study drug and all were mild in nature and resolved completely."

Adverse events • P1/2 data • Hepatitis C Virus